ClinicalTrials.gg
RecruitingNCT00537004Updated Feb 27, 2026

Language in Primary Progressive Aphasia

An observational study in Primary Progressive Aphasia, sponsored by Northwestern University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Northwestern University · Observational

From the registry’s dates

  • Started May 2007; still recruiting 19 years 6 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Study summary

The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.

Read the detailed description

The Language in Primary Progressive Aphasia (PPA) aims to understand the behavioral, anatomical and physiological changes in people with PPA throughout the course of the illness. The researchers in this study want to increase awareness of PPA, educate others about this unique disorder, and to encourage more research to eventually develop therapies.

During the three-day research program, participants will be asked to undergo neuropsychological testing (paper and pencil tests that evaluate cognition), advanced imaging (MRI and PET), cognitive experiments, and other computer and language testing batteries. Participants may be asked to return every two years to complete the same measures.

For participants not living near Chicago, IL, flights and accommodations (for both the person with PPA and their companion) will be covered by the study.

02

Conditions studied

  • Primary Progressive Aphasia

Keywords

  • primary progressive aphasia
  • frontotemporal dementia
  • semantic dementia
  • progressive nonfluent aphasia
  • progressive aphasia
  • frontotemporal lobar degeneration
03

In context

Aphasia, Primary Progressive

77 studies on the registry are indexed under Aphasia, Primary Progressive; 29 are open to participants now.

This study's planned enrollment of 500 is above the median of 166 across 14 observational studies indexed under Aphasia, Primary Progressive.

Browse Aphasia, Primary Progressive studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,423 studies on the registry; 198 are open to participants now.

Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with PPA will be recruited from the Northwestern University Alzheimer's Disease Center Core registry, the Northwestern University Neurobehavior and Memory Clinic, and from those who contact the center that are interested in PPA research.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary progressive aphasia
  • Right-handed
  • Native English speaker
  • Visual acuity of 20/30 corrected
  • Adequate hearing to follow conversation
  • Safe for an MRI scan

Exclusion criteria

Exclusion Criteria:

  • Left-handedness
  • Claustrophobia
  • Presence of significant medical illness that initially or in the future could interfere with continued participation in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)

Groups and cohorts

  • PPA (Primary Progressive Aphasia)

    Individuals with primary progressive aphasia

  • Control

    Individuals with no diagnosis of any type of dementia

06

What researchers measure

Primary outcomes

  1. Neuropsychological variables

    Time frame: Immediately after testing and at two years post-testing

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol. 1982 Jun;11(6):592-8. doi: 10.1002/ana.410110607. PubMed 7114808 ↗
  • Weintraub S, Rubin NP, Mesulam MM. Primary progressive aphasia. Longitudinal course, neuropsychological profile, and language features. Arch Neurol. 1990 Dec;47(12):1329-35. doi: 10.1001/archneur.1990.00530120075013. PubMed 2252450 ↗
  • Mesulam MM, Coventry C, Kuang A, Bigio EH, Mao Q, Flanagan ME, Gefen T, Sridhar J, Geula C, Zhang H, Weintraub S, Rogalski EJ. Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia. Neurology. 2021 Feb 9;96(6):e916-e925. doi: 10.1212/WNL.0000000000011397. Epub 2021 Jan 13. PubMed 33441454 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00537004
Responsible party
Marsel Mesulam (Director, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University) — Principal investigator
First posted
Sep 28, 2007
Start date
May 2007
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Elizabeth A Haynes
Contact
PPA.Research@northwestern.edu
312-503-2398
Marsel Mesulam, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion